VisionGate
Phoenix
About VisionGate
VisionGate is dedicated to saving lives through early cancer detection and prevention, utilizing its revolutionary automated 3D cell imaging platform that is capable of generating high-resolution 3D biosignatures from intact cells. It is a clinical-stage oncology pharmaceutical and diagnostics company. Their lead diagnostic product is the LuCED lung test - a non-invasive sputum-based test that detects abnormal cells which indicate lung cancer and bronchial dysplasia. It was founded by Alan Nelson and is based in Phoenix, Arizona.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $58.2M
- Last round: Series Unknown (Dec 2019)
- Website: visiongate3d.com
- Phone: 6023689107
Industries & Categories
Biotechnology, Health Care, Life Science, Wellness
Social Profiles
Canonical: https://fsome.com/organization/visiongate-13954 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.